{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:11:34Z","timestamp":1792509094962,"version":"4.5.0"},"reference-count":68,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T00:00:00Z","timestamp":1316390400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0025065","type":"journal-article","created":{"date-parts":[[2011,9,19]],"date-time":"2011-09-19T21:25:35Z","timestamp":1316467535000},"page":"e25065","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":109,"title":["Receptor-Mediated Endocytosis of \u03b1-Galactosidase A in Human Podocytes in Fabry Disease"],"prefix":"10.1371","volume":"6","author":[{"given":"Thaneas","family":"Prabakaran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rikke","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob V.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren S.","family":"S\u00f8rensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla Feldt-","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moin A.","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus M.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre J.","family":"Verroust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik I.","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2011,9,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM196705252762101","article-title":"Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.","volume":"276","author":"RO Brady","year":"1967","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1126\/science.167.3922.1268","article-title":"Fabry's disease: alpha-galactosidase deficiency.","volume":"167","author":"JA Kint","year":"1970","journal-title":"Science"},{"key":"ref3","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease.","author":"RJ Desnick","year":"2006"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.","volume":"34","author":"A Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/bmj.1.5082.1266","article-title":"The renal lesion in angiokeratoma corporis diffusum.","volume":"1","author":"JR Colley","year":"1958","journal-title":"Br Med J"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000059897","article-title":"Kidney involvement in Anderson-Fabry disease.","volume":"122","author":"M Meroni","year":"1997","journal-title":"Contrib Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00005792-200203000-00003","article-title":"Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course.","volume":"81","author":"MH Branton","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/ki.2010.484","article-title":"Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.","volume":"79","author":"B Najafian","year":"2011","journal-title":"Kidney Int"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1046\/j.1523-1755.2002.00097.x","article-title":"Patients with Fabry disease on dialysis in the United States.","volume":"61","author":"R Thadhani","year":"2002","journal-title":"Kidney Int"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00007890-200006150-00020","article-title":"Excellent outcome of renal transplantation in patients with Fabry's disease.","volume":"69","author":"A Ojo","year":"2000","journal-title":"Transplantation"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ki.1978.32","article-title":"Early renal changes in hemizygous and heterozygous patients with Fabry's disease.","volume":"13","author":"MC Gubler","year":"1978","journal-title":"Kidney Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","article-title":"Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.","volume":"62","author":"BL Thurberg","year":"2002","journal-title":"Kidney Int"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1053\/j.ajkd.2007.12.032","article-title":"Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria.","volume":"51","author":"C Tondel","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"S134","DOI":"10.1097\/01.ASN.0000016684.07368.75","article-title":"Renal pathology in Fabry disease.","volume":"13","author":"J Alroy","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2003.09.022","article-title":"Fabry disease: renal involvement limited to podocyte pathology and proteinuria in a septuagenarian cardiac variant. Pathologic and therapeutic implications.","volume":"43","author":"SM Meehan","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0016-5085(65)80041-5","article-title":"Inborn Lysosomal Diseases.","volume":"48","author":"HG Hers","year":"1965","journal-title":"Gastroenterology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.","volume":"97","author":"R Schiffmann","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","article-title":"Enzyme replacement therapy in Fabry disease: a randomized controlled trial.","volume":"285","author":"R Schiffmann","year":"2001","journal-title":"JAMA"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.","volume":"68","author":"CM Eng","year":"2001","journal-title":"Am J Hum Genet"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","article-title":"Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.","volume":"21","author":"R Schiffmann","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","article-title":"Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.","volume":"18","author":"R Schiffmann","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","article-title":"Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.","volume":"18","author":"DP Germain","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.","volume":"146","author":"M Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1681\/ASN.2008080870","article-title":"Agalsidase alfa and kidney dysfunction in Fabry disease.","volume":"20","author":"M West","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.","volume":"374","author":"A Mehta","year":"2009","journal-title":"Lancet"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2013replacement therapy in Fabry's disease.","volume":"345","author":"CM Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"ref27","first-page":"823","article-title":"Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease.","volume":"2","author":"FC Fervenza","year":"2008","journal-title":"Biologics"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","article-title":"Clinical benefit of enzyme replacement therapy in Fabry disease.","volume":"69","author":"F Breunig","year":"2006","journal-title":"Kidney Int"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","article-title":"Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg.","volume":"2","author":"AC Vedder","year":"2007","journal-title":"PloS ONE"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/ndt\/gfp105","article-title":"Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.","volume":"24","author":"B Oqvist","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"12115","DOI":"10.1016\/S0021-9258(18)63825-6","article-title":"Mannose 6-phosphate receptors and lysosomal enzyme targeting.","volume":"264","author":"NM Dahms","year":"1989","journal-title":"J Biol Chem"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/0092-8674(77)90262-8","article-title":"Recognition and receptor-mediated uptake of a lysosomal enzyme, alpha-l-iduronidase, by cultured human fibroblasts.","volume":"12","author":"GN Sando","year":"1977","journal-title":"Cell"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1073\/pnas.74.5.2026","article-title":"Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts.","volume":"74","author":"A Kaplan","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1681\/ASN.2006080822","article-title":"Distribution of alpha-galactosidase A in normal human kidney and renal accumulation and distribution of recombinant alpha-galactosidase A in Fabry mice.","volume":"18","author":"EI Christensen","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1681\/ASN.V133630","article-title":"A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression.","volume":"13","author":"MA Saleem","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/emboj\/18.3.595","article-title":"Propeptide cleavage conditions sortilin\/neurotensin receptor-3 for ligand binding.","volume":"18","author":"C Munck Petersen","year":"1999","journal-title":"EMBO J"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1093\/glycob\/cwg034","article-title":"A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease.","volume":"13","author":"K Lee","year":"2003","journal-title":"Glycobiology"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"26273","DOI":"10.1074\/jbc.273.41.26273","article-title":"The 100-kDa neurotensin receptor is gp95\/sortilin, a non-G-protein-coupled receptor.","volume":"273","author":"J Mazella","year":"1998","journal-title":"J Biol Chem"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/nrn2516","article-title":"VPS10P-domain receptors - regulators of neuronal viability and function.","volume":"9","author":"TE Willnow","year":"2008","journal-title":"Nat Rev Neurosci"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","article-title":"Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.","volume":"54","author":"H Rahmoune","year":"2005","journal-title":"Diabetes"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1152\/physrev.1976.56.3.502","article-title":"Transport of molecules across renal glomerular capillaries.","volume":"56","author":"BM Brenner","year":"1976","journal-title":"Physiol Rev"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"12491","DOI":"10.1073\/pnas.211291398","article-title":"Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia.","volume":"98","author":"R Kozyraki","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1038\/sj.ki.5000133","article-title":"Detection of bile salt-dependent lipase, a 110 kDa pancreatic protein, in urines of healthy subjects.","volume":"69","author":"B Comte","year":"2006","journal-title":"Kidney Int"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/ki.1993.113","article-title":"IGF-II\/Man-6-P receptors in rat kidney: apical localization in proximal tubule cells.","volume":"43","author":"S Cui","year":"1993","journal-title":"Kidney Int"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1210\/endo-123-2-774","article-title":"Specific, high affinity receptors for insulin-like growth factor II in the rat kidney glomerulus.","volume":"123","author":"JF Haskell","year":"1988","journal-title":"Endocrinology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","article-title":"Structure and function of the mannose 6-phosphate\/insulinlike growth factor II receptors.","volume":"61","author":"S Kornfeld","year":"1992","journal-title":"Annu Rev Biochem"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1016\/S0021-9258(17)39385-7","article-title":"Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process.","volume":"260","author":"Y Oka","year":"1985","journal-title":"J Biol Chem"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1074\/jbc.272.6.3599","article-title":"Molecular identification of a novel candidate sorting receptor purified from human brain by receptor-associated protein affinity chromatography.","volume":"272","author":"CM Petersen","year":"1997","journal-title":"J Biol Chem"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1074\/jbc.273.6.3582","article-title":"Sortilin is the major 110-kDa protein in GLUT4 vesicles from adipocytes.","volume":"273","author":"NJ Morris","year":"1998","journal-title":"J Biol Chem"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nrm778","article-title":"Megalin and cubilin: multifunctional endocytic receptors.","volume":"3","author":"EI Christensen","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1046\/j.1523-1755.2002.00501.x","article-title":"The tandem endocytic receptors megalin and cubilin are important proteins in renal pathology.","volume":"62","author":"PJ Verroust","year":"2002","journal-title":"Kidney Int"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.157.2.667","article-title":"Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats.","volume":"157","author":"D Kerjaschki","year":"1983","journal-title":"J Exp Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1159\/000076404","article-title":"Differentiation-induced cultured podocytes express endocytically active megalin, a heymann nephritis antigen.","volume":"96","author":"H Yamazaki","year":"2004","journal-title":"Nephron Exp Nephrol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/ki.1990.135","article-title":"Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells.","volume":"37","author":"HJ Grone","year":"1990","journal-title":"Kidney Int"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"F674","DOI":"10.1152\/ajprenal.00272.2006","article-title":"Statin-sensitive endocytosis of albumin by glomerular podocytes.","volume":"292","author":"J Eyre","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"26172","DOI":"10.1016\/S0021-9258(18)35732-6","article-title":"Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance.","volume":"267","author":"TE Willnow","year":"1992","journal-title":"J Biol Chem"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"19417","DOI":"10.1074\/jbc.270.33.19417","article-title":"Glycoprotein 330\/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100.","volume":"270","author":"S Stefansson","year":"1995","journal-title":"J Biol Chem"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"21162","DOI":"10.1016\/S0021-9258(19)36811-5","article-title":"The 39-kDa receptor-associated protein interacts with two members of the low density lipoprotein receptor family, alpha 2-macroglobulin receptor and glycoprotein 330.","volume":"267","author":"MZ Kounnas","year":"1992","journal-title":"J Biol Chem"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0014-5793(98)00559-6","article-title":"The carboxy-terminal domain of the receptor-associated protein binds to the Vps10p domain of sortilin.","volume":"429","author":"J Tauris","year":"1998","journal-title":"FEBS Lett"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.1073\/pnas.79.18.5557","article-title":"The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border.","volume":"79","author":"D Kerjaschki","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jconrel.2008.12.006","article-title":"In vitro and in vivo evaluation of a non-carbohydrate targeting platform for lysosomal proteins.","volume":"135","author":"JE Stefano","year":"2009","journal-title":"J Control Release"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.0308728100","article-title":"Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice.","volume":"101","author":"JH LeBowitz","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"35037","DOI":"10.1074\/jbc.M402630200","article-title":"Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase.","volume":"279","author":"WS Prince","year":"2004","journal-title":"J Biol Chem"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"16564","DOI":"10.1016\/S0021-9258(19)85456-X","article-title":"Epithelial glycoprotein-330 mediates endocytosis of plasminogen activator-plasminogen activator inhibitor type-1 complexes.","volume":"268","author":"SK Moestrup","year":"1993","journal-title":"J Biol Chem"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1083\/jcb.141.3.815","article-title":"Mannose 6-phosphate\/insulin-like growth factor-II receptor targets the urokinase receptor to lysosomes via a novel binding interaction.","volume":"141","author":"A Nykjaer","year":"1998","journal-title":"J Cell Biol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1093\/emboj\/20.9.2180","article-title":"The sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting protein.","volume":"20","author":"MS Nielsen","year":"2001","journal-title":"EMBO J"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1042\/bj0890114","article-title":"The Preparation of I-131-Labelled Human Growth Hormone of High Specific Radioactivity.","volume":"89","author":"FC Greenwood","year":"1963","journal-title":"Biochem J"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1172\/JCI8862","article-title":"Cubilin is an albumin binding protein important for renal tubular albumin reabsorption.","volume":"105","author":"H Birn","year":"2000","journal-title":"J Clin Invest"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0025065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,5]],"date-time":"2021-12-05T16:40:50Z","timestamp":1638722450000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0025065"}},"subtitle":[],"editor":[{"given":"Jean-Claude","family":"Dussaule","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,19]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0025065","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,19]]}}}